Multiple subsequent studies indicated that high levels of Bcl-2 gene expression correlate with severity of malignancy in cancer patients, including melanoma, breast, prostate, small cell lung, colorectal and bladder cancer, while increased Bcl-2 expression is associated with resistance to chemotherapy and radiation [53]. Here, BCL2 is linked to urinary bladder carcinoma.